Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Dissecting the pathogenesis of classical Hodgkin lymphoma (cHL), a common cancer in young adults, remains challenging because of the rarity of tumor cells in involved tissues (usually <5%). Here, we analyzed the coding genome of cHL by microdissecting tumor and normal cells from 34 patient biopsies for a total of ∼50 000 singly isolated lymphoma cells. We uncovered several recurrently mutated genes, namely, STAT6 (32% of cases), GNA13 (24%), XPO1 (18%), and ITPKB (16%), and document the functional role of mutant STAT6 in sustaining tumor cell viability. Mutations of STAT6 genetically and functionally cooperated with disruption of SOCS1, a JAK-STAT pathway inhibitor, to promote cHL growth. Overall, 87% of cases showed dysregulation of the JAK-STAT pathway by genetic alterations in multiple genes (also including STAT3, STAT5B, JAK1, JAK2, and PTPN1), attesting to the pivotal role of this pathway in cHL pathogenesis and highlighting its potential as a new therapeutic target in this disease.

[1]  F. Cavalli,et al.  Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy , 2017 .

[2]  A. Rosenwald,et al.  Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. , 2016, Blood.

[3]  A. Ng,et al.  Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. , 2016, Hematology. American Society of Hematology. Education Program.

[4]  Peter W. M. Johnson,et al.  Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? , 2016, Hematology. American Society of Hematology. Education Program.

[5]  R. Carlson,et al.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Jardin,et al.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma , 2016, Haematologica.

[8]  R. Küppers,et al.  Hodgkin lymphoma: Pathology and biology. , 2016, Seminars in hematology.

[9]  I. Lossos,et al.  GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. , 2016, Blood.

[10]  M. Shipp,et al.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer , 2016, Proceedings of the National Academy of Sciences.

[11]  Hailong Meng,et al.  Recurrent genetic defects in classical Hodgkin lymphoma cell lines , 2016, Leukemia & lymphoma.

[12]  K. Sauer,et al.  Non-canonical antagonism of PI3K by the kinase Itpkb delays thymocyte β-selection and renders it Notch-dependent , 2016, eLife.

[13]  S. Keir,et al.  Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program , 2016, Pediatric blood & cancer.

[14]  C. Copie-Bergman,et al.  Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study , 2016, Clinical Cancer Research.

[15]  J. Byrd,et al.  Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies , 2015, Leukemia.

[16]  A. Letai,et al.  Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice , 2016, Leukemia.

[17]  J. Cyster,et al.  The G protein–coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination , 2015, The Journal of experimental medicine.

[18]  Ryan D. Morin,et al.  Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.

[19]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[20]  A. Rosenwald,et al.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.

[21]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[22]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[23]  E. Vanstreels,et al.  Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. , 2015, Chemistry & biology.

[24]  M. Kaminski,et al.  Activating STAT6 mutations in follicular lymphoma. , 2015, Blood.

[25]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[26]  R. Gascoyne,et al.  The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing , 2014, Leukemia.

[27]  K. Elenitoba-Johnson,et al.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. , 2014, Blood.

[28]  Adrien B. Larsen,et al.  Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.

[29]  E. Baloglu,et al.  Clinical translation of nuclear export inhibitors in cancer. , 2014, Seminars in cancer biology.

[30]  A. Razak,et al.  Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. , 2014, Cancer discovery.

[31]  R. Gascoyne,et al.  Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma , 2014, Nature Genetics.

[32]  S. Monti,et al.  Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo , 2014, Clinical Cancer Research.

[33]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[34]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[35]  Yazmin P. Carrasco,et al.  Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1 , 2013, Proceedings of the National Academy of Sciences.

[36]  R. Küppers.  New insights in the biology of Hodgkin lymphoma. , 2012, Hematology. American Society of Hematology. Education Program.

[37]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[38]  W. Klapper,et al.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. , 2012, Blood.

[39]  Yuh Min Chook,et al.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. , 2012, Blood.

[40]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[41]  J. Cyster,et al.  S1PR2 links germinal center confinement and growth regulation , 2012, Immunological reviews.

[42]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[43]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[44]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[45]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[46]  Luciano Galdieri,et al.  Gene-Specific Repression of Proinflammatory Cytokines in Stimulated Human Macrophages by Nuclear IκBα , 2010, The Journal of Immunology.

[47]  R. Gascoyne,et al.  Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. , 2010, Blood.

[48]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[49]  R. Siebert,et al.  Mutations of NFKBIA, encoding IκBα, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non‐EBV‐associated cases , 2009, International journal of cancer.

[50]  Gwendoline Dubois,et al.  Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. , 2009, Blood.

[51]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[52]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[53]  R. Küppers,et al.  Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. , 2009, Annual review of pathology.

[54]  W. Klapper,et al.  Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by array-based comparative genomic hybridization , 2008, Haematologica.

[55]  I. Lossos,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. , 2005, Blood.

[56]  G. Mills,et al.  Inhibition of the phosphatidylinositol‐3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma , 2005, British journal of haematology.

[57]  T. Mattfeldt,et al.  Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. , 2005, Oncogene.

[58]  L. Young,et al.  Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR , 2005, The Journal of pathology.

[59]  Karen Leroy,et al.  Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. , 2004, Blood.

[60]  H. Stein,et al.  Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells , 2003, The Journal of pathology.

[61]  I. Vancurova,et al.  NF-κB Regulation in Human Neutrophils by Nuclear IκBα: Correlation to Apoptosis1 , 2002, The Journal of Immunology.

[62]  R. Gascoyne,et al.  Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2002, Blood.

[63]  A. van den Berg,et al.  TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein‐Barr virus , 2001, International journal of cancer.

[64]  V. Diehl,et al.  Clonal Deleterious Mutations in the Iκbα Gene in the Malignant Cells in Hodgkin's Lymphoma , 2000, The Journal of experimental medicine.

[65]  H. Stein,et al.  Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. , 1999, Blood.

[66]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[67]  T. Colby,et al.  Interfollicular Hodgkin's disease , 1983, The American journal of surgical pathology.